Provided by Tiger Fintech (Singapore) Pte. Ltd.

KALA BIO

4.30
-0.1500-3.37%
Post-market: 4.300.00000.00%16:09 EDT
Volume:18.09K
Turnover:78.30K
Market Cap:27.75M
PE:-0.56
High:4.54
Open:4.33
Low:4.25
Close:4.45
Loading ...

Kala Bio Inc. Officer Romulus K. Brazzell Reports Disposal of Common Shares

Reuters
·
05 Jun

KALA BIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
23 May

Kala Pharmaceuticals price target lowered to $12 from $15 at H.C. Wainwright

TIPRANKS
·
23 May

Kala Bio Q1 EPS $(1.41) Beats $(2.03) Estimate

Benzinga
·
14 May

Kala Bio Inc. Reports Q1 2025 Financials: Decrease in G&A and R&D Expenses, Cash Resources Expected to Fund Operations into 2026

Reuters
·
14 May

BRIEF-Kala Bio Q1 EPS USD -1.41

Reuters
·
14 May

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
14 May

KALA BIO Q1 EPS USD -1.41

THOMSON REUTERS
·
14 May

KALA BIO Inc expected to post a loss of $2.03 a share - Earnings Preview

Reuters
·
09 May

Kala Pharmaceuticals (KALA) Receives a Buy from Oppenheimer

TIPRANKS
·
14 Apr

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

KALA BIO Advances Eye Disease Therapies with New Funding

TIPRANKS
·
01 Apr

Kala Bio Q4 EPS $(1.74) Beats $(2.28) Estimate

Benzinga
·
31 Mar

BRIEF-Kala Bio Q4 EPS USD -1.74

Reuters
·
31 Mar

KALA BIO Q4 Income From Operations USD -9.459 Million

THOMSON REUTERS
·
31 Mar

KALA BIO Q4 EPS USD -1.74

THOMSON REUTERS
·
31 Mar

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
31 Mar

KALA BIO Inc expected to post a loss of $2.28 a share - Earnings Preview

Reuters
·
25 Mar

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
26 Feb

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb